Advertisement
Canada markets close in 5 hours 32 minutes

  • S&P/TSX

    21,731.38
    -142.34 (-0.65%)
     

  • S&P 500

    5,011.94
    -59.69 (-1.18%)
     

  • DOW

    37,813.66
    -647.26 (-1.68%)
     

  • CAD/USD

    0.7296
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    82.31
    -0.50 (-0.60%)
     

  • Bitcoin CAD

    87,448.28
    -2,329.48 (-2.59%)
     

  • CMC Crypto 200

    1,379.18
    -3.40 (-0.25%)
     

  • GOLD FUTURES

    2,335.70
    -2.70 (-0.12%)
     

  • RUSSELL 2000

    1,965.53
    -29.90 (-1.50%)
     

  • 10-Yr Bond

    4.7190
    +0.0670 (+1.44%)
     

  • NASDAQ

    15,493.58
    -219.17 (-1.39%)
     

  • VOLATILITY

    17.13
    +1.16 (+7.24%)
     

  • FTSE

    8,055.70
    +15.32 (+0.19%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6804
    -0.0015 (-0.22%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?

Zacks Equity Research

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ACADIA Pharmaceuticals (ACAD) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

ACADIA Pharmaceuticals is one of 883 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ACAD is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ACAD's full-year earnings has moved 9.02% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

ADVERTISEMENT

Our latest available data shows that ACAD has returned about 179.47% since the start of the calendar year. At the same time, Medical stocks have gained an average of 11.02%. This means that ACADIA Pharmaceuticals is outperforming the sector as a whole this year.

Looking more specifically, ACAD belongs to the Medical - Biomedical and Genetics industry, which includes 374 individual stocks and currently sits at #62 in the Zacks Industry Rank. On average, this group has gained an average of 10.18% so far this year, meaning that ACAD is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to ACAD as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.